Verona_Pharma_Dark_medium.jpg
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
August 02, 2017 11:00 ET | Verona Pharma plc
LONDON, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference
August 01, 2017 07:00 ET | Verona Pharma plc
LONDON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment
July 26, 2017 02:00 ET | Verona Pharma plc
LONDON, July 26, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe
June 27, 2017 02:00 ET | Verona Pharma plc
LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs
June 22, 2017 07:00 ET | Verona Pharma plc
LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA
June 05, 2017 08:30 ET | Verona Pharma plc
LONDON, June 05, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference
May 23, 2017 08:30 ET | Verona Pharma plc
LONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment Option
May 18, 2017 14:09 ET | Verona Pharma plc
LONDON, May 18, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative...
Verona_Pharma_Dark_medium.jpg
Grant of Options and RSUs and PDMR Dealings
May 03, 2017 10:08 ET | Verona Pharma plc
LONDON, May 03, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces Closing of Global Offering
May 02, 2017 13:53 ET | Verona Pharma plc
LONDON, May 02, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative...